ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1405

Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis

Research Methodology Poster – ARP

10:30AM-12:30PM: Abstract Number: 1001

Perceived Mistreatment in Patients with Rheumatic Diseases: The Impact of the Underlying Diagnosis

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1015

Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1438

Performance of Combined MRI SI Joint Active and Structural Lesions in Diagnosing Axial SpA: A Prospective Cohort Study

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1617

Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1369

Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0890

Pervasive Inflammation Poisons Hematopoiesis and Drives Clonal Dominance in VEXAS Syndrome

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1016

Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1085

Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1005

Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1175

Physical Activity and Symmetry Following Total Knee Arthroplasty:Results of an Exploratory Trial

Orthopedics, Low Back Pain, & Rehabilitation – ACR/ARP Poster

10:30AM-12:30PM: Abstract Number: 1302

Physician Knowledge, Attitudes and Perceived Barriers to Recommending the Recombinant Varicella Zoster Vaccine

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1053

Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1413

Pilot Trial of Ustekinumab for Primary Sjogren’s Syndrome

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1112

Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].